Nervgen Pharma Corp (NGENF)

$2.54 +0.05 (2.01%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 124,100
Avg Vol 103,690
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 91%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Rexpower
Rexpower Aug. 23 at 8:27 PM
$NGENF , now with the recent rodent hearing loss result Nervgen has to be attempting to work with the VA or department of defense to get a human trial going for hearing loss. The VA/DoD already has a large patient population they can reach out to. There's isnt any costly physical therapy that has to be given like SCI. Plus the VA will probably cover the cost of the before and after hearing test. The trail should be quick and inexpensive.
0 · Reply
salmonberryak
salmonberryak Aug. 23 at 12:17 PM
$NGENF a participant in the NVG291 spinal cord injury chronic cohort said that a secondary effect of taking the drug was improved sense of smell, not just gaining mobility. It seems it can repair all types of nerve damage, which is why there are so many use cases (dementia, MS, traumatic brain injury). Scientific American just published an article about the possibility of nerve repair, the same science used by Nervgen. https://www.scientificamerican.com/article/how-scientists-finally-learned-that-nerves-regrow-even-in-the-adult-brain/
1 · Reply
badprecog
badprecog Aug. 22 at 3:10 PM
$NGENF Anyone know for dumb people if it fixed the nerves for the hearing loss or if it somehow fixed what was going on in the brain?
1 · Reply
PETESHICK
PETESHICK Aug. 22 at 2:10 PM
$NGENF volume’s still low. Once we get going a little more I expect volume will increase dramatically! Then we’re off running! Patiently waiting…
1 · Reply
Buckeye250
Buckeye250 Aug. 22 at 12:46 PM
$NGENF I hope that communications like yesterdays continue because this gives me a lot of confidence that new management is done with the old ways of being secretive. A new chapter for NervGen!
0 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 22 at 2:06 AM
$NGENF*two Department of Defense sponsored studies * significant functional recovery in models of blast-induced sensorineural hearing loss and peripheral nerve injury *build on the recently announced CONNECT SCI Study *Conducted by the U.S. Air Force's 59th Medical Wing in collaboration with the Uniformed Services University, Brooke Army Medical Center *treatment led to statistically significant improvements in hearing thresholds across all frequencies by end-of-study at Day 30 *This could fundamentally change how we manage acute acoustic trauma on the battlefield and beyond. *Researchers at Washington University School of Medicine in St. Louis investigated NVG-291-R *NVG-291 could play a critical role in improving outcomes for individuals with peripheral nerve damage in both military and civilian populations." When this info comes from an independent source, adds creditability. Next up is FDA meeting next month.
2 · Reply
shopno
shopno Aug. 21 at 8:37 PM
$NGENF
3 · Reply
RenDragon
RenDragon Aug. 21 at 8:25 PM
$NGENF I’ve been wondering for some time whether any of the subjects in the trial also had tinnitus (like me). And whether any changes had been noticed. This report suggests there maybe some hope for the future. As more people move through the spinal cord trials you would think some of them might also have hearing issues that can be followed.
2 · Reply
MarianoItaliano
MarianoItaliano Aug. 21 at 7:49 PM
$NGENF they basically need to get approval for anything asap then the revenue stream will open doors for next potential applications of NVG-291 and NVG-300. Looking at this now it looks like a sci wasn't the lowest hanging fruit here
2 · Reply
PETESHICK
PETESHICK Aug. 21 at 6:18 PM
$NGENF I’m thinking that Management has a game plan to support the stock. I suspect we may be seeing more frequent updates in the coming weeks similar to today’s up until some big news. Seems like we may finally be on our way!
4 · Reply
Latest News on NGENF
No data available.
Rexpower
Rexpower Aug. 23 at 8:27 PM
$NGENF , now with the recent rodent hearing loss result Nervgen has to be attempting to work with the VA or department of defense to get a human trial going for hearing loss. The VA/DoD already has a large patient population they can reach out to. There's isnt any costly physical therapy that has to be given like SCI. Plus the VA will probably cover the cost of the before and after hearing test. The trail should be quick and inexpensive.
0 · Reply
salmonberryak
salmonberryak Aug. 23 at 12:17 PM
$NGENF a participant in the NVG291 spinal cord injury chronic cohort said that a secondary effect of taking the drug was improved sense of smell, not just gaining mobility. It seems it can repair all types of nerve damage, which is why there are so many use cases (dementia, MS, traumatic brain injury). Scientific American just published an article about the possibility of nerve repair, the same science used by Nervgen. https://www.scientificamerican.com/article/how-scientists-finally-learned-that-nerves-regrow-even-in-the-adult-brain/
1 · Reply
badprecog
badprecog Aug. 22 at 3:10 PM
$NGENF Anyone know for dumb people if it fixed the nerves for the hearing loss or if it somehow fixed what was going on in the brain?
1 · Reply
PETESHICK
PETESHICK Aug. 22 at 2:10 PM
$NGENF volume’s still low. Once we get going a little more I expect volume will increase dramatically! Then we’re off running! Patiently waiting…
1 · Reply
Buckeye250
Buckeye250 Aug. 22 at 12:46 PM
$NGENF I hope that communications like yesterdays continue because this gives me a lot of confidence that new management is done with the old ways of being secretive. A new chapter for NervGen!
0 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 22 at 2:06 AM
$NGENF*two Department of Defense sponsored studies * significant functional recovery in models of blast-induced sensorineural hearing loss and peripheral nerve injury *build on the recently announced CONNECT SCI Study *Conducted by the U.S. Air Force's 59th Medical Wing in collaboration with the Uniformed Services University, Brooke Army Medical Center *treatment led to statistically significant improvements in hearing thresholds across all frequencies by end-of-study at Day 30 *This could fundamentally change how we manage acute acoustic trauma on the battlefield and beyond. *Researchers at Washington University School of Medicine in St. Louis investigated NVG-291-R *NVG-291 could play a critical role in improving outcomes for individuals with peripheral nerve damage in both military and civilian populations." When this info comes from an independent source, adds creditability. Next up is FDA meeting next month.
2 · Reply
shopno
shopno Aug. 21 at 8:37 PM
$NGENF
3 · Reply
RenDragon
RenDragon Aug. 21 at 8:25 PM
$NGENF I’ve been wondering for some time whether any of the subjects in the trial also had tinnitus (like me). And whether any changes had been noticed. This report suggests there maybe some hope for the future. As more people move through the spinal cord trials you would think some of them might also have hearing issues that can be followed.
2 · Reply
MarianoItaliano
MarianoItaliano Aug. 21 at 7:49 PM
$NGENF they basically need to get approval for anything asap then the revenue stream will open doors for next potential applications of NVG-291 and NVG-300. Looking at this now it looks like a sci wasn't the lowest hanging fruit here
2 · Reply
PETESHICK
PETESHICK Aug. 21 at 6:18 PM
$NGENF I’m thinking that Management has a game plan to support the stock. I suspect we may be seeing more frequent updates in the coming weeks similar to today’s up until some big news. Seems like we may finally be on our way!
4 · Reply
Rexpower
Rexpower Aug. 21 at 5:50 PM
$NGENF anyone who is in any military, hearing loss of peripheral nerve injury groups(Facebook, reddit, discord...) should share this article. Just get the word out.
1 · Reply
philmitchell
philmitchell Aug. 21 at 4:21 PM
$NGENF Today’s news release stated that improvements in hearing were observed in as little as four weeks. So if this holds true with humans then this could mean that ears and hands are two areas that will show the fastest improvements from treatment with NVG-291. The next question is what other areas would naturally follow? From the one participant in the study, the nose might be in this fastest improvement group of the body as well.
1 · Reply
Buckeye250
Buckeye250 Aug. 21 at 2:38 PM
$NGENF Fingers crossed that the Department of Defense will now support NVG-291 in getting accelerated approval for use in both civilian and military populations
2 · Reply
EBLSA4X
EBLSA4X Aug. 21 at 12:52 PM
$NGENF Some good news today. Needs to be confirmed in the clinic, but should be a much easier trial to recruit. https://nervgen.com/nervgen-pharmas-nvg-291-r-demonstrates-significant-functional-recovery-in-department-of-defense-sponsored-preclinical-models-of-traumatic-hearing-loss-and-peripheral-nerve-injury/
4 · Reply
newsfile_corp
newsfile_corp Aug. 21 at 11:31 AM
https://nfne.ws/263280 $NGENF $NGEN.TSXV @nervgenp #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #OTC #OT
1 · Reply
timfris
timfris Aug. 20 at 12:32 PM
$NGENF seems to be promising drug that offers a lot of hope for patients and investors, but unfortunately ran by amateurs without a clue on how to monopolize it. Partner with someone that knows what they’re doing or sell company.
1 · Reply
AuriniaBeach
AuriniaBeach Aug. 20 at 11:17 AM
$NGENF A new Blink of an Eye podcast just dropped, #276 Understanding the chemistry of NVG-291’s efficacy for Rewiring SCI Recovery with Inventor Dr. Brad Lang. Dr. Lang worked in Dr. Jerry Silver’s lab on the Intracellular Sigma Peptide. https://podcasts.apple.com/us/podcast/blink-of-an-eye/id1526474466?i=1000722778980
4 · Reply
Lectin_Pectin
Lectin_Pectin Aug. 19 at 7:48 PM
$NGENF MEP tests specifically measure direct CST signals, which are less critical for legs after spinal cord injury (SCI). Legs often recover through alternative pathways that aren't captured by MEP, allowing functional gains like better walking without signal changes in the TA muscle. This "dissociation" between MEP results and real-world function is a known issue in SCI research—electrophysiological tests like MEP can miss broader adaptations.
2 · Reply
MarianoItaliano
MarianoItaliano Aug. 19 at 3:44 PM
$NGENF imo it's irrational to sell now. They've said 3/4 quarter there will be feedback from FDA so why selling before the news?
0 · Reply
Boxbcn24
Boxbcn24 Aug. 19 at 3:37 PM
$NGENF so from canada open we go 8% up and directly again to 2.03, algos or what? Who will sell this little profit after so much down?
2 · Reply
rwelsh633
rwelsh633 Aug. 19 at 2:49 PM
$NGENF quarterly report was released on Aug. 22nd last year. I'd assume it should be out anytime now. Maybe they will give us some sort of company update.
0 · Reply
Boxbcn24
Boxbcn24 Aug. 18 at 8:00 PM
$NGENF really crazy here, so we have some drug with never seen results and we are going bellow that when we are waiting to finish the trial... but no word from Netherlands CO. Let me be clear who is silent viewing the bleeding of your CO? we have to wait for FDA meeting, until now no data schedule or info.. but this smells like an acquisition. Waiting here but less patient.
2 · Reply